Andrew is a Radiopharmaceutical Science Specialist with expertise in design, synthesis, and characterisation of radiotracers for diagnostic and therapeutic applications towards human health. Andrew recently completed his Ph.D. at Macquarie University in collaboration with the Australian Nuclear Science and Technology Organisation (ANSTO) in the field of radiopharmaceutical sciences. During his Ph.D. Andrew investigated new approaches to label peptide radiotracers using heteroatom-fluorine techniques as well as developing radioimmunoconjugates using both site-specific and non-site-specific approaches.
Since 2024, Andrew holds a cross appointment between the Prince of Wales Hospital and the Biological Resource Imaging Laboratory (BRIL), at UNSW as a Radiochemist. He is also a National Imaging Facility Radiochemistry Fellow. Andrew has a strong interest in developing radiotracers and radiopharmaceuticals to address challenges in research and healthcare applications.
The Australian Epilepsy Project has seven MRI scanning sites across five states as part of a national network to provide epilepsy patients with access to advanced diagnostic testing that was otherwise
15 October 2025
The scans at NeuRA Imaging, the UNSW Node of the National Imaging Facility, revealed decreased conductivity in several white-matter areas of the brain, plus increased levels of chemicals indicating br
07 July 2025
Donanemab, developed by Lilly, is the first disease-modifying treatment for early-stage Alzheimer’s disease to be approved for use in Australia. The National Imaging Facility supported its developme
16 June 2025
Dr Sicong Tu is excited about helping motor neurone disease (MND) patients gain a much better idea of their disease progression: “The focus of our network is on bridging the gap between leading Aust
28 May 2025